Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 0.58 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.53 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.53 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.48 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.48 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21296757 | 0.95 | HRH3 (0.57) | HRH3ADRA1DADRA1AADRA1BKDM4E | |
| SCHEMBL29937951 | 0.89 | HRH3 (0.61) | HRH3ADRA1DADRA1AADRA1BKDM4E | |
| SCHEMBL29938322 | 0.87 | ADRA1D (0.60) | HRH3ADRA1DADRA1AADRA1BKDM4E | |
| SCHEMBL21296815 | 0.82 | NR1H4 (0.51) | HDAC1CACNA1B | |
| SCHEMBL21296796 | 0.81 | NR1H4 (0.55) | CACNA1B | |
| SCHEMBL21296758 | 0.81 | HDAC2 (0.50) | HDAC1CACNA1BMAPTRXFP1 | |
| SCHEMBL29938178 | 0.80 | HRH3 (0.59) | HRH3KDM4ERXFP1 | |
| SCHEMBL29937772 | 0.77 | GAA (0.71) | HRH3ADRA1DADRA1AADRA1BKDM4E | |
| SCHEMBL21296843 | 0.75 | KMT2A (0.56) | HDAC1MAPT | |
| SCHEMBL21296806 | 0.74 | MEN1 (0.49) | KDM4EALDH1A1HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11530181-B2 | IL-6 inhibitors and methods of treatment | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2022-12-20 | — | — | US | claimed |
| US-20210206718-A1 | IL-6 INHIBITORS AND METHODS OF TREATMENT | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED | 2021-07-08 | — | — | US | claimed |
| WO-2019165158-A1 | IL-6 INHIBITORS AND METHODS OF TREATMENT | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2019-08-29 | — | — | WO | claimed |
| US-20240246943-A1 | MULTIFACETED APPROACH TO NOVEL INTERLEUKIN-6 INHIBITORS | University of Florida Research Fooundation, Incorporated (US) | 2024-07-25 | — | — | US | disclosed |
| US-11530181-B2 | IL-6 inhibitors and methods of treatment | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2022-12-20 | — | — | US | disclosed |
| US-11530181-B2 | IL-6 inhibitors and methods of treatment | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2022-12-20 | — | — | US | disclosed |
| WO-2022226133-A1 | MULTIFACETED APPROACH TO NOVEL INTERLEUKIN-6 INHIBITORS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2022-10-27 | — | — | WO | disclosed |
| US-20210206718-A1 | IL-6 INHIBITORS AND METHODS OF TREATMENT | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED | 2021-07-08 | — | — | US | disclosed |
| US-20210206718-A1 | IL-6 INHIBITORS AND METHODS OF TREATMENT | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED | 2021-07-08 | — | — | US | disclosed |
| WO-2019165158-A1 | IL-6 INHIBITORS AND METHODS OF TREATMENT | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2019-08-29 | — | — | WO | disclosed |
| WO-2019165158-A1 | IL-6 INHIBITORS AND METHODS OF TREATMENT | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2019-08-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11530181-B2 | IL-6 inhibitors and methods of treatment | IL6, IL6ST, IL2 | HRH3 1534/4885ADRA1D 3229/4885ADRA1A 2843/4885 |
| US-20240246943-A1 | MULTIFACETED APPROACH TO NOVEL INTERLEUKIN-6 INHIBITORS | IL6, IL6ST, IL36G | HRH3 3168/4885ADRA1D 3531/4885ADRA1A 3472/4885 |
| US-20210206718-A1 | IL-6 INHIBITORS AND METHODS OF TREATMENT | IL6, IL6ST, IL2 | HRH3 1534/4885ADRA1D 3229/4885ADRA1A 2843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.